Home › Research › Cognitive tests and assessment
CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease
Madison I. J. Honey, Yanaika Sylvana Hok-A-Hin, Elisabeth H. Thijssen, Babette van der Weijden, Erik Stoops, Sterre C.M. de Boer, Flora Hillegonde Duits, Emma Louise van der Ende et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
AcTau174 levels were elevated in all dementia groups compared to controls, with a stepwise increase from controls to MCI-AD (2.2-fold) to AD dementia (3.5-fold, Figure 1). The strongest increase compared to controls was observed in the FTD group, wherein AcTau174 distinguished FTD from controls with a high area under the curve (AUC) accuracy of 0.95 (95%CI:0.92;0.99), significantly outperforming CSF pTau181 (AUC=0.65, 95%CI:0.55;0.75) and CSF Tau (AUC=0.83, 95%CI:0.75;0.91). AcTau174 showed high accuracy for differentiating AD (AUC=0.98, 95%CI:0.96;0.99) and MCI-AD (AUC=0.89, 95%CI:0.84;0.93) from controls (Figure 2). In FTD, AcTau174 correlated with MMSE (ρ=-0.29, p =0.039), and in AD with the frontal assessment battery score (ρ=-0.35, p =0.0001). In FTD, higher baseline CSF AcTau174 was associated with a faster rate of decline in MMSE over time (β=-1.64, 95%CI:-2.61;-0.87, p =0.0014, Figure 3), which was not observed for CSF pTau181 or Tau. Higher baseline CSF AcTau174 also predicted faster MMSE decline within AD (β=-1.66, 95%CI:-2.44;-0.90, p <0.0001) and MCI-AD (β=-0.67, 95%CI:-1.09;-0.27, p =0.002, Figure 3). CSF AcTau174 shows great diagnostic value across neurodegenerative dementias and is strongly associated with clinical progression. In FTD, where trials are limited by clinical heterogeneity and lack of fluid biomarkers, AcTau174 may aid in identifying patients at risk of rapid decline, supporting trial enrichment and more targeted intervention strategies. Its predictive capacity for MMSE decline highlights its potential as a progression biomarker, both for patient monitoring and therapeutic development.
What this study adds
Evidence grade: Moderate
This study found that a form of acetylated tau in spinal fluid was elevated in several dementias and was linked to faster cognitive decline. Reported effect size: AUC=0.65; AUC=0.83; AUC=0.98.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Honey, M. I. J., Hok-A-Hin, Y. S., Thijssen, E. H., van der Weijden, B., Stoops, E., de Boer, S. C., et al. (2025). CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70861_108639
Vancouver
Honey MIJ, Hok-A-Hin YS, Thijssen EH, van der Weijden B, Stoops E, de Boer SC, et al. CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70861_108639. PMID: 41434517.
BibTeX
@article{honey2025-41434517,
author = {Honey, Madison I. J. and Hok-A-Hin, Yanaika Sylvana and Thijssen, Elisabeth H. and van der Weijden, Babette and Stoops, Erik and de Boer, Sterre C.M. and Duits, Flora Hillegonde and van der Ende, Emma Louise and others},
title = {{CSF Acetylated Tau‐174 as a novel diagnostic and prognostic biomarker in Frontotemporal Dementia and Alzheimer’s Disease}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70861_108639},
pmid = {41434517},
url = {https://doi.org/10.1002/alz70861_108639}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- AcTau174 levels were elevated in all dementia groups compared to controls, with a stepwise increase from controls to MCI-AD (2.2-fold) to AD dementia (3.5-fold, Figure 1).
- The strongest increase compared to controls was observed in the FTD group, wherein AcTau174 distinguished FTD from controls with a high area under the curve (AUC) accuracy of 0.95 (95%CI:0.92;0.99), significantly outperforming CSF pTau181 (AUC=0.65, 95%CI:0.55;0.75) and CSF Tau (AUC=0.83, 95%CI:0.75;0.91).
- AcTau174 showed high accuracy for differentiating AD (AUC=0.98, 95%CI:0.96;0.99) and MCI-AD (AUC=0.89, 95%CI:0.84;0.93) from controls (Figure 2).
- In FTD, AcTau174 correlated with MMSE (ρ=-0.29, p =0.039), and in AD with the frontal assessment battery score (ρ=-0.35, p =0.0001).
- In FTD, higher baseline CSF AcTau174 was associated with a faster rate of decline in MMSE over time (β=-1.64, 95%CI:-2.61;-0.87, p =0.0014, Figure 3), which was not observed for CSF pTau181 or Tau.
Why it matters
This study found that a form of acetylated tau in spinal fluid was elevated in several dementias and was linked to faster cognitive decline. It may help diagnose and predict progression, but it is a biomarker study and does not test any treatment.
Study details
- Effect sizeAUC=0.65; AUC=0.83; AUC=0.98
- Evidence strengthModerate
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Charlotte Elisabeth Teunissen: h-index 116 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Weill Cornell Medicine: institution h-index 1,163 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41434517) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70861_108639
- PubMed: 41434517
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.